---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058191"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:00:49.491054+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q1 2024 revenue $17.6M, net income $8.6M; cash runway into H2 2026

## Summary
- Revenue $17.6M (up from $8.8M YoY); net income $8.6M vs loss $25.1M in Q1 2023.
- Cash and equivalents $137.8M; cash runway extended into H2 2026 via $40M equity offering.
- PBGENE-HBV on track for IND/CTA filing in 2024; PBGENE-PMM expected in 2025.
- iECURE's OTC gene editing program opened enrollment in UK, first in vivo ARCUS trial.
- Regained rights to three preclinical programs (DMD, liver, CNS) from Prevail collaboration.

## SEC filing metadata
- accession: 0000950170-24-058191
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017024058191/0000950170-24-058191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017024058191/dtil-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058191
- JSON: https://secwatch.observer/filing/0000950170-24-058191.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.